ByTrending Posts
BioNextAI Media Report: Merck-Mayo Clinic AI Pact—5 Petabytes…
Published by BioNextAI Media – Merck has forged a high-octane research collaboration with Mayo Clinic, fusing 5 petabytes of…
BioNextAI Media Report: Keytruda’s Ovarian Cancer Combo Triumph—28%…
Published by BioNextAI Media – Merck’s KEYTRUDA (pembrolizumab) delivered compelling Phase 3 data from combination regimens in ovarian cancer,…
BioNextAI Media Report: Merck’s Gardasil Cuts—$200M Savings, 150…
Published by BioNextAI Media – In a calculated response to softening markets, Merck is halting production of its HPV…
Merck’s Bold Pivot: Can Dividing Oncology from the…
Merck’s audacious restructuring of its pharmaceutical operations into standalone oncology and non-oncology divisions isn’t mere corporate tinkering—it’s a…
Lilly’s $2.4B Bet on In Vivo CAR-T: Acquiring…
Eli Lilly and Company revealed plans in early February 2026 to acquire Orna Therapeutics, a cutting-edge biotech company…
Can Eli Lilly’s Orforglipron Overtake Novo Nordisk’s Rybelsus…
Indianapolis, Ind., 2026 — Eli Lilly and Company today announced positive head-to-head Phase 3 results demonstrating that its…
Is Bayer’s Lawsuit Against Johnson & Johnson Escalating…
Leverkusen, Germany — Bayer AG has filed a lawsuit in U.S. federal court against Johnson & Johnson, alleging…
Is Johnson & Johnson’s $1 Billion Pennsylvania Investment…
New Brunswick, N.J. — Johnson & Johnson today announced plans to invest more than $1 billion to construct…
Is Johnson & Johnson Preparing to Divest DePuy…
Will Johnson & Johnson’s Orthopedics Review Reshape the Global MedTech Landscape? Johnson & Johnson is reportedly exploring a…
Trending Posts
Latest Stories
Is Roche’s $480M Bet Making South Korea Asia’s Next Biopharma Powerhouse?
Roche’s $480M Bet on South Korea Signals a Strategic Pivot to Asia’s AI–Oncology Powerhouse Roche…
PepGen’s DMD Gene Therapy Hit with FDA Partial Hold—A Warning Sign for Biotech Pipeline Timelines
PepGen’s DMD Gene Therapy Hit with FDA Partial Hold—A Warning Sign for Biotech Pipeline Timelines…
Blackstone’s $400M Bet on Teva–Sanofi Gut Drug Signals a Major Shift in the IBD Landscape
Blackstone has invested $400 million into Teva and Sanofi’s experimental ulcerative colitis (UC) and Crohn’s disease therapy,…
Has China Now Overtaken the US at the Heart of Biotech Innovation?
Recent data from JPM2026 shows that China has surpassed the United States in key biotech…
Gallery
